TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Warming Mattress on Perioperative Hypothermia Following Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* will be age \>18 years,~* singleton pregnancy \>37 weeks,~* neuraxial anesthesia,~* healthy afebrile patients.~Exclusion Criteria:~* • will be age \>18 years,~  * singleton pregnancy \>37 weeks,~ * neuraxial anesthesia,~ * healthy afebrile patients.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Underbody warmer on (Type: EXPERIMENTAL): Underbody warmer will be underneath the patient and turned on.
- Underbody warmer off (Type: PLACEBO_COMPARATOR): Underbody warmer will be underneath the patient but not turned on.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk Factor Control Before Orthopedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • ≥ 21 years of age~  * Subjects undergoing open orthopedic surgery of the hip, knee or spine~ * Surgery is scheduled at least 3 days after PAT visit and no more than 14 days.~ * High risk subject cohort~    * Coronary artery disease, or~   * Cerebrovascular disease (prior stroke, TIA or carotid artery disease (\>70% stenosis), or~   * Peripheral artery disease, or~   * Prior Venous thromboembolism or arterial thromboembolism, or~   * Age ≥ 60 years and 2 of the following~ * Renal insufficiency (creatinine clearance \< 60ml/min)~ * Diabetes~ * COPD~ * Hypertension~ * Active smoker or stopped less than 30 days prior to consent~ * Cancer (excluding BCC)~ * Heart Failure~Exclusion Criteria:~* • Known intolerance to statins~  * Subject is already on maximum dose statin (atorvastatin/Lipitor 80mg daily or rosuvastatin/crestor 40mg daily)~ * Bilateral renal artery stenosis~ * End stage renal disease (receiving dialysis or CrCl \<30ml/min)~ * Known allergy or intolerance to ACE-inhibitor (other than cough) or Angiotensin receptor blocker (e.g. angioedema, hyperkalemia)~ * Known allergy or intolerance to beta blockers~ * Known sick sinus syndrome not treated with permanent pacemaker~ * Known greater than first degree AV block not treated with a pacemaker~ * Excessive alcohol intake~ * Acute Coronary Syndrome requiring hospitalization within 1 month~ * Stroke within 1 month~ * Known pregnancy~ * Severe co-morbid condition with life expectancy \< 6 months~ * Inability to give informed consent or adhere to follow-up as per protocol~ * Current participation in another investigational drug or device trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: ACTIVE_COMPARATOR): Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
- Control (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Airway Pressure Release Ventilation and Intracranial Pressure in Patients With Severe Traumatic Brain Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Intracranial Pressure Monitoring device present~* Mechanically Ventilated~* Clinically Stable as determined by the Critical Care attending~Exclusion Criteria:~* Age \<14~* Prisoners~* Initial Mode of ventilation is APRV~* Provider's Judgement~* Pregnant

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Airway Pressure Release Ventilation:APRV (Type: None): Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
- Low Tidal Volume Ventilation:LOTV (Type: None): Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MOTO Post-marketing Surveillance Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with unicompartmental tibiofemoral osteoarthritis (OA) of the knee that meet the indications for use of Medacta implant included in this study (on-label use);~* Patients suffering from unilateral osteoarthritis or osteonecrosis of a single knee compartment;~* Frontal deformity \< 10° (evaluated on weight-bearing long-axis x-rays);~* Flexion contracture \< 10°;~* Intact ligaments;~* Patients willing and able to provide written informed consent for participation in the study;~* Patient's age over 18 years old;~* Patient with BMI \< 40 kg/m2;~* Patients willing to comply with the pre and post-operative evaluation schedule.~Exclusion Criteria:~* Patients with one or more medical conditions identified as a contraindication in the labelling on any Medacta implants used in this study;~* Any patient who cannot or will not provide informed consent for participation in the study;~* Patients who need a revision surgery;~* Patients who had previously undergone high tibial osteotomy or anterior cruciate ligament (ACL) reconstruction;~* Patients with BMI ≥ 40 kg/m2;~* Patients unable to understand and take action;~* Any case not described in the inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MOTO medial (Type: None): Patients suitable fulfilling the standard criteria for the implantation of unicondylar implant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Apomorphine-induced Skin Reactions: a Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Female and male subjects aged ≥30;~* Diagnosis of idiopathic Parkinson's disease of \>3 years' duration, defined by the United Kingdom (UK) Brain Bank criteria, with the exception of \>1 affected relative being allowed, without any other known or suspected cause of Parkinsonism (Gibb \& Lees, 1988);~* Treatment with continuous subcutaneous apomorphine infusion;~* Having apomorphine-induced skin reactions (i.e. erythema, swelling and/or nodule formation);~* Male and female patients must be compliant with a highly effective contraceptive method (oral hormonal contraception alone is not considered highly effective and must be used in combination with a barrier method) during the study, if sexually active;~* Subjects considered reliable and capable of adhering to the protocol, visit schedule, and medication intake according to the judgement of the investigator.~Exclusion Criteria:~* High suspicion of other parkinsonian syndromes;~* History of respiratory depression;~* Hypersensitivity to hydrocortisone or any excipients of the medicinal product;~* Concomitant therapy with histamine antagonist;~* Known with Cushing's disease or hypercortisolism~* Any medical condition that is likely to interfere with an adequate participation in the study including e.g. current diagnosis of unstable epilepsy; clinically relevant cardiac dysfunction and/or myocardial infarction or stroke within the last 12 months;~* Pregnant and breastfeeding women;~* Current infectious disease with fever at the time of investigation.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Massage with a spiky ball (Type: ACTIVE_COMPARATOR): Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
- Hydrocortisone cream 1% (Type: ACTIVE_COMPARATOR): Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
- Subcutaneous hydrocortisone 10mg (Type: ACTIVE_COMPARATOR): Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
- Apomorphine 0.25% (2.5mg/ml) (Type: ACTIVE_COMPARATOR): Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject \>= 18 years;~* Histologically or cytologically confirmed, metastatic or locally advanced unresectable HER2-positive;~* Adequate organ function assessed within 7 days prior to first trial treatment~* ECOG score 0 or 1;~* Left ventricular ejection fraction (LVEF) ≥ 50% at baseline;~* Life expectancy \>3 months~Exclusion Criteria:~* Untreated active CNS metastasis or leptomeningeal metastasis;~* Uncontrolled tumor-related pain;~* Has received other anti-tumor treatment or an investigational drug within 28 days or within 5 times of half-life (whichever is shorter, and no less than 2 weeks) prior to the first trial treatment;~* Major surgery for any reason within 28 days;~* Curative radiation within 3 months of the first dose of trial treatment;~* History of uncontrolled intercurrent illness;~* Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- dose-escalation Phase (Type: None): KN026 20 mg/kg + palbociclib125 mg/day+Fulvestrant 500 mg (Patients with HR+/HER2-positive MBC )
- parallel-group expansion Phase (Type: None): KN026 20 mg/kg + palbociclib +Fulvestrant 500 mg(Patients with HR+/HER2-positive MBC )

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 55-85y;~* Diagnosis of COVID-19;~* Hospitalized patients.~Exclusion Criteria:~* Active heart disease or active cancer at time of recruitment;~* Patients in Intensive Care Unit at the time of recruitment;~* Patents with alanine transaminase and aspartate transaminase greater than 5 times the upper limit of normal at any time;~* Patients requiring \>4L per minute of oxygen support at the time of recruitment.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Active arm (Type: EXPERIMENTAL): The active supplements are glycine and N-acetylcysteine
- Placebo arm (Type: PLACEBO_COMPARATOR): The placebo arm is alanine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed genetic diagnosis of Prader-Willi Syndrome~* Age 12-65~* Obesity~* Age 12-17: BMI ≥ 95th percentile for age and gender~* Age 18-65: BMI ≥27 to ≤60 kg/m2~Exclusion Criteria:~* Subjects living in a group home ≥ 50% of the time~* Recent use (within 3 months) of weight loss agents including herbal medication~* Poorly controlled severe psychiatric disorders

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Intervention: ZGN-440 Placebo for Injectable Suspension
- ZGN-440 Injectable Suspension (1.8 mg) (Type: EXPERIMENTAL): Intervention: ZGN-440 for Injectable Suspension
- ZGN-440 Injectable Suspension (2.4 mg) (Type: EXPERIMENTAL): Intervention: ZGN-440 for Injectable Suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients in the age of 18 to 70 years~* Having a recent positive direct test for Sars-CoV-2~* Having mild or moderate COVID-19 symptoms with no indication for hospitalization due to SARS-CoV-2 infection (WHO Ordinal Scale 1-2)~Exclusion Criteria:~* Severe respiratory symptoms related to COVID-19 requiring oxygen or intensive care (high flow oxygen or mechanical ventilation or ECMO)~* Patients with preexisting pulmonary diseases requiring oxygen supply~* Patients with history of hypersensitivity to Camostat or Niclosamide or to any ingredients to any of the two drugs~* Patients with heart failure (NYHA III or NYHA IV)~* Patients with proven malignant tumor~* Patients diagnosed with influenza infection~* Pregnancy or breastfeeding~* Immunocompromised patients~* Creatinine clearance \< 60 mL/min~* aspartate aminotransferase (AST) / alanine aminotransferase (ALT) \> 2 times upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Niclosamide + Camostat (Type: ACTIVE_COMPARATOR): Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo orally over a period of 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Verticalization on Intracranial Hemodynamics Assessed in Transcranial Doppler at the Acute Phase of Cerebral Infarction

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ischemic stroke (AIC) or transient ischemic attack (AIT) of the carotid artery~* Duration of symptoms less than 48 hours~* Absence of homolateral or downstream intracranial stenosis or occlusion M1~* Lifting authorized by the referent clinician.~* Rankin's score before AIC/AIT ≤ 2~  • For cases:~* Carotid stenosis of more than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion~  • For controls:~* Absence of carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or occlusion~Exclusion Criteria:~- Disrupted vigilance~Secondary exclusion criteria:~* Absence of a homolateral temporal acoustic window at the lesion~* Impossibility to verticalize the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cases (Type: None): Patients with ischemic stroke or transient ischemic attack who have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.
- Controls (Type: None): Patients with ischemic stroke or transient ischemic attack who do not have carotid stenosis greater than 50% NASCET (North American Symptomatic Carotid Endarterectomy Trial) or an occlusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14 and 24 weeks of gestation~* Both nulliparous and multiparous women~* An unfavorable cervix (Bishop's score less than 8)~Exclusion Criteria:~* Known contraindications to the use of prostaglandins (e.g. asthma)~* Previous uterine scar (previous cesarean or myomectomy where the endometrial cavity was entered)

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
- B (Type: ACTIVE_COMPARATOR): Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Infant Formula Trial on Dietary Management of Infantile Colic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants aged 21-56 days (both inclusive);~2. Gestation age 37-42 weeks;~3. Normal birth weight for gestational age and gender~4. 5-minute APGAR score \>7;~5. Diagnosed with infantile colic ;~6. Fully formula fed for at least 7 days before randomisation;~7. Written informed consent from the parent and/or legal representative.~Exclusion Criteria:~1. Any plausible cause of inconsolable crying as judged by the investigator;~2. Presence of non-functional vomiting or failure to thrive;~3. Presence of any congenital defects in the gastrointestinal system or other defects preventing oral nutrition;~4. Congenital condition and/or previous or current illness/infection and (or) medication use that could interfere with the main study outcomes;~5. Known cow's milk protein allergy, lactose intolerance, or galactosaemia; including presence of any allergic manifestations;~6. Received any special formula (e.g. lactose-free, hydrolysed protein);~7. Received any of the following products/medication within 7 days before randomisation:~   1. Probiotics~  2. Systemic antibiotics~  3. Prokinetics~  4. Proton pump inhibitors~8. Twins or triplets or other infant(s) \<6 months of age living in the same household;~9. Incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements;~10. Current participation in another clinical study involving investigational or marketed products.

- Gender: ALL
- Minimum Age: 21 Days
- Maximum Age: 56 Days
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
- Control group (Type: ACTIVE_COMPARATOR): Standard cow's milk with prebiotics mixture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analysis T Cells Response for Identification of Aspergillus Bronchitis With Cystic Fibrosis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with cystic fibrosis followed at Resource Centers and Cystic Fibrosis Skills (CRCM) Montpellier~* Patient aged 15 or over~* Patient able to understand the nature, purpose and methodology of the study.~* Patient and his legal representative for minors who have given their free and informed consent~* Affiliate or beneficiary of a social security scheme.~Exclusion Criteria:~* Patients on antifungal treatment at the time of sampling~* Pregnant or breastfeeding~* Major protected by law (guardianship, curator or under Backup Justice)~* Inability to understand the nature and goals of the study and / or communication difficulties with the investigator~* Subject attending another search including a period of exclusion still going to run-in

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cystic fibrosis (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues